Mar 10, 2021 / 11:45AM GMT
Presentation of Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE and ENGAGE at AD/PD
Mar 10, 2021 / 11:45AM GMT
=====================
Corporate Participants
=====================
* Laura Nisenbaum
=====================
Laura Nisenbaum -
Hello. My name is Laura Nisenbaum, I am the Head of the Diagnostic Pathways Group at Biogen and lead the biomarker strategy for aducanumab. It's my pleasure to present our work on cerebrospinal fluid biomarker concordance with amyloid PET from EMERGE and ENGAGE, our Phase III studies of aducanumab in patients with early Alzheimer's disease.
Before moving into the results from my presentation, I provide here the disclosures from the authors of this work. I want to note that aducanumab is an investigational compound and is not yet approved.
Finally, please note that this presentation may include forward-looking statements as detailed here. The data described in this presentation come from the EMERGE and ENGAGE Phase III aducanumab trials. These studies were identical in design, randomized, 18-month
Biogen Inc Pre-Recorded Presentation of Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE and ENGAGE at AD/PD Transcript
Mar 10, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers